Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascot is sniffing about in search of varmint. As for us, we are as busy as ever hunting and gathering items of interest. We trust you have your own hectic agendas. So join us as we hoist the ever-present cup of stimulation and attack the to-do list. Have a grand day, everyone, and do stay in touch. …
After two years of contentious bargaining, a U.S. bankruptcy court judge approved a controversial plan that will dissolve Purdue Pharma, which has been blamed for triggering a widespread opioid crisis, and shield members of the Sackler family who control the company from future lawsuits, STAT reports. The settlement calls for some Sackler family members to contribute more than $4.3 billion over a decade to compensate people, local governments, and tribal communities that were harmed by the OxyContin painkiller. Appeals are expected.
The Food and Drug Administration asked Pfizer (PFE), Eli Lilly (LLY), and AbbVie (ABBV) to include information about the risks of serious conditions and death from the use of their drugs that belong to a class of treatments known as JAK inhibitors, Reuters notes. The warnings stem from an agency review of Pfizer’s arthritis drug Xeljanz after initial results from a February trial showed an increased risk of serious heart-related problems and cancer with the drug.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
